Once-weekly basal insulin: A measured advance
Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh · 01.07.2026 · 5 (2) · e90516
DOI: 10.3329/jacedb.v5i2.90516 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh, online erschienen am 01.07.2026. Verfasst von Md Mohsin Sarker. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Insulin icodec, the first once-weekly basal insulin analogue, addresses a longstanding barrier to insulin initiation: the burden of daily injections. By binding reversibly to albumin via a C20 fatty diacid chain, icodec achieves a half-life of approximately 196 hours, enabling stable glucose lowering throughout the week from a single subcutaneous dose. Across the ONWARDS phase 3 program, icodec demonstrated at least noninferior, and in several trials statistically superior, glycated hemoglobin (HbA1c) reduction compared with once-daily basal insulin analogues in type 2 diabetes. The hypoglycemia signal was variable across type 2 diabetes trials but consistently and significantly elevated in type 1 diabetes. The prolonged pharmacokinetic profile confers an important limitation: dosing errors carry sustained consequences, and the effects of an administered dose cannot be rapidly reversed. For patients in whom injection burden is the primary barrier to insulin initiation, a once-weekly option may resolve years of clinical inertia. Nevertheless, this is a measured advance. Clinicians must weigh the convenience of weekly dosing against pharmacokinetic inflexibility, a modest but present hypoglycemia signal, and access barriers that may exclude the patients who stand to benefit most. [J Assoc Clin Endocrinol Diabetol Bangladesh, July 2026; 5 (2): e90516]
Zitieren
APA
Sarker, M. M. (2026). Once-weekly basal insulin: A measured advance. Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh, 5(2), e90516. https://doi.org/10.3329/jacedb.v5i2.90516
Vancouver
Sarker MM. Once-weekly basal insulin: A measured advance. Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh. 2026;5(2):e90516. doi:10.3329/jacedb.v5i2.90516
BibTeX
@article{Sarker2026,
author = {Sarker, Md Mohsin},
title = {Once-weekly basal insulin: A measured advance},
journal = {Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh},
year = {2026},
volume = {5},
number = {2},
pages = {e90516},
doi = {10.3329/jacedb.v5i2.90516}
}
EUVIMED